Neurology International最新文献

{"title":"Neurological Sequelae of Acute Hydrogen Sulfide Poisoning: A Literature Review, Controversies, and Knowledge Gaps.","authors":"Wilson K Rumbeiha, Dong-Suk Kim","doi":"10.3390/neurolint17050071","DOIUrl":"10.3390/neurolint17050071","url":null,"abstract":"<p><p>Hydrogen sulfide (H₂S) is a highly potent toxic gas, and the brain is a primary target organ following acute intoxications. Accidents and misuse of this gas for nefarious purposes, i.e., bioterrorism, are causes for concern regarding acute poisoning. The immediate effects of acute H₂S poisoning are well known. Numerous publications have reported neurological sequelae, including insomnia, persistent headaches, ataxia, cognition deficits, hearing impairment, dysarthria, and neuropsychiatric behaviors, among survivors of acute H₂S poisoning. However, this subject remains controversial. The goal of this study was to review the literature on acute H₂S-poisoning-induced neurological sequelae and on animal models to determine prevalence and knowledge gaps. We also reviewed the literature on cyanide-induced neurological sequelae. The results of large population studies indicate that the majority of victims of acute H₂S poisoning survive. There is a lack of patient follow-up and standardized neuropsychological, neurological, and neuroimaging for accurate assessments. We observed flaws in animal models that failed to recapitulate the severe neurotoxicity induced via the inhalation route. We observed a paucity of literature on cyanide-induced neurological sequelae. In contrast to cyanide-induced sequelae, predominantly characterized by Parkinsonian-like motor behavioral deficits, H₂S patients exhibit mostly cognition deficits, speech impairment, and neuropsychological effects. This first comprehensive review of neurological sequelae induced by H₂S and cyanide poisonings identified knowledge gaps in the prevalence of these sequelae and cellular and molecular mechanisms underlying them. It is unclear whether these sequelae are reversible. There are no FDA-approved drugs for the prevention or treatment of these sequelae. Notably, patients who received life-saving therapy still developed delayed neurological sequelae.</p>","PeriodicalId":19130,"journal":{"name":"Neurology International","volume":"17 5","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12113851/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144151224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Concurrent Chronic Heart Failure and Chronic Kidney Dysfunction on Post-Stroke Rehabilitation Outcomes.","authors":"Azadeh Fischer, Nadja Jauert, Martin Schikora, Michael Joebges, Wolfram Doehner","doi":"10.3390/neurolint17050070","DOIUrl":"10.3390/neurolint17050070","url":null,"abstract":"<p><p><b>Background/Objectives:</b> The aim of this study was to evaluate the impact of chronic heart failure (CHF), chronic kidney dysfunction (CKD), and the combined CHF-CKD comorbidity on the outcomes of rehabilitation in stroke patients. <b>Methods:</b> A total of 586 patients who had suffered a stroke (mean age, 70 ± 13; 47.6% female; 72.4% ischemic and 27.6% hemorrhagic strokes) and who were admitted immediately after acute stroke care to a rehabilitation center were included in this cohort study and followed up with until their death or discharge from the rehabilitation center. The clinical characteristics of the patients were obtained from their medical records. The relationship between the background comorbidities (CHF, CKD, and concurrent CHF-CKD) and fatal and non-fatal unfavorable outcomes (emergency readmission to a primary hospital or transfer to a long-term care facility in a vegetative or minimally conscious state) were investigated. <b>Results:</b> Unfavorable outcomes were more common in the groups with background CHF and/or CKD. From the Cox multivariate analysis, both CHF and CKD were independent prognostic factors for the occurrence of unfavorable outcomes, with a hazard ratio (HR) of 2.28 (95% CI = 1.2-4.29; <i>p</i>-value = 0.01) and 2.19 (95% CI = 1.24-3.87; <i>p</i>-value = 0.007), respectively. Moreover, the combined CHF-CKD comorbidity showed a more than 5-fold increased risk of an adverse post-stroke outcome (HR of 5.8; 95% CI = 2.5-13.44; <i>p</i>-value < 0.001). <b>Conclusions:</b> The combined CHF-CKD comorbidity is an important independent complicating factor that, along with other known influencing factors, can affect unfavorable post-stroke outcomes more than CHF or CKD alone, and necessitates critical attention to its diagnosis and management as a separate mixed syndrome.</p>","PeriodicalId":19130,"journal":{"name":"Neurology International","volume":"17 5","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12113819/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144151229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Cilostazol and Aspirin During Hyperacute Stroke Phase in Rats: An Experimental Research Study.","authors":"Christiana Anastasiadou, Anastasios Papapetrou, George Galyfos, Kostas Vekrellis, Patroklos Katafygiotis, Andreas Lazaris, George Geroulakos, Angelos Megalopoulos, Christos Liapis, Nikolaos Kostomitsopoulos, John Kakisis","doi":"10.3390/neurolint17050069","DOIUrl":"10.3390/neurolint17050069","url":null,"abstract":"<p><strong>Objective: </strong>The contralateral hippocampus, a critical region for cognitive function, is often overlooked in everyday clinical practice and stroke research. This study aimed to evaluate the effect of specific antiplatelet agents on the hippocampus (ipsilateral and contralateral) during the hyperacute phase of stroke.</p><p><strong>Materials and methods: </strong>Twelve-week-old rats were randomly assigned to four groups, each containing six rats: a cilostazol group, an aspirin group, an aspirin plus cilostazol group, and a control group. Each substance was administered for four weeks. Permanent brain ischemia was induced over 2 h using intraluminal middle cerebral artery occlusion. A neurologic examination was conducted, followed by euthanasia and histological examination of the CA1 hippocampal region. The hematoxylin and eosin stain was used to assess the total number of intact neuronal cell bodies and pyknotic nuclei, an indicator of early irreversible neuronal injury.</p><p><strong>Results: </strong>In the ipsilateral hippocampus, monotherapy with either aspirin or cilostazol significantly reduced pyknotic nuclei compared with the control group (<i>p</i> = 0.0016 and <i>p</i> = 0.0165, respectively). However, combination therapy showed no significant difference from the controls (<i>p</i> = 0.2375). In the contralateral hippocampus, cilostazol monotherapy demonstrated significantly reduced pyknotic nuclei (<i>p</i> = 0.0098), whereas aspirin monotherapy and combination therapy did not (<i>p</i> = 0.1009 and <i>p</i> = 0.9999, respectively). A cumulative analysis of both hemispheres revealed that monotherapy with aspirin or cilostazol markedly reduced injury markers (<i>p</i> = 0.0002 and <i>p</i> = 0.0001, respectively), whereas combined therapy revealed no significant benefit (<i>p</i> = 0.1984). A neurological assessment indicated that the most severe deficits were in the combination therapy group.</p><p><strong>Conclusions: </strong>To the best of our knowledge, this is the first study to compare acute histopathological changes in the affected and unaffected hippocampus after a stroke in a rat model. Dual antiplatelet therapy resulted in worse outcomes (histopathological and neurological) than monotherapy.</p>","PeriodicalId":19130,"journal":{"name":"Neurology International","volume":"17 5","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12114208/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144151071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intravascular Large B-Cell Lymphoma Diagnosed After Recurrent Stroke: Case Report and Literature Review.","authors":"Naoko Takaku, Koji Hayashi, Mamiko Sato, Rei Asano, Kouji Hayashi, Toyoaki Miura, Norimichi Shirafuji, Tadanori Hamano, Yasutaka Kobayashi","doi":"10.3390/neurolint17050068","DOIUrl":"10.3390/neurolint17050068","url":null,"abstract":"<p><p><b>Background/Objectives</b>: We describe a case of intravascular large B-cell lymphoma (IVLBCL) presenting with recurrent cerebral infarctions and review similar reported cases. Our aim is to explore potential early diagnostic markers and discuss their prognostic implications. <b>Methods/Results</b>: A 79-year-old man with a history of hypertension, hyperuricemia, and postoperative bladder cancer presented with five to six cerebral infarctions over an 11-month period, despite successive changes in antiplatelet and anticoagulant medications. Neurological examination revealed decreased pain sensation, bilateral hearing loss, and right thenar atrophy. Laboratory studies showed elevated inflammatory markers and soluble IL-2 receptor. CSF analysis revealed elevated protein, β2-microglobulin, IL-6, and IL-10 levels. A skin biopsy was performed to investigate suspected IVLBCL. Histopathological examination of the skin biopsy revealed large pleomorphic CD20-positive cells within the vasculature, confirming a diagnosis of IVLBCL. The patient was treated with chemotherapy, including dose-adjusted R-CHOP and high-dose methotrexate, and achieved complete remission. No recurrence of cerebral infarction was observed during a two-year follow-up period. <b>Conclusions</b>: This case highlights the importance of considering IVLBCL in patients with recurrent strokes of unknown etiology, especially when laboratory or imaging findings suggest systemic involvement. Early recognition and appropriate tissue diagnosis, such as skin biopsy, are essential for timely treatment and favorable prognosis.</p>","PeriodicalId":19130,"journal":{"name":"Neurology International","volume":"17 5","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12114279/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144151218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Association of Cerebral Blood Flow Measured Using Extracranial Carotid Ultrasound with Functional Outcomes in Patients with Anterior Circulation Large Vessel Occlusion After Endovascular Thrombectomy-A Retrospective Study.","authors":"Xin-Hong Lin, Kuan-Wen Chen, Chung-Fu Hsu, Ting-Wei Chang, Chao-Yu Shen, Hsin-Yi Chi","doi":"10.3390/neurolint17050067","DOIUrl":"10.3390/neurolint17050067","url":null,"abstract":"<p><p><b>Background</b>: Endovascular mechanical thrombectomy (EVT) is regarded as the standard treatment for acute ischemic stroke with large vessel occlusion. Few studies have examined the evolution of cerebral flow after the acute stage of ischemic stroke. In this study, we examined the association of functional outcomes with cerebral blood flow by extracranial carotid sonography during the subacute phase after EVT and multiple prognostic variables. <b>Methods</b>: We conducted a single-center, retrospective, observational study between January 2018 and June 2023. Patients with acute stroke resulting from anterior circulation large vessel occlusion who underwent EVT were included. All patients underwent carotid sonography in the second week after EVT. Patients with fair (modified Rankin Scale [mRS]: 0-3) and poor outcomes (mRS: 4-6) were compared to determine the association between and identify the predictors of these factors and functional outcomes. <b>Results</b>: A total of 89 patients were included (female: 38 (42.7%); mean age: 69.45 ± 13.59 years). Multivariable logistic regression analysis revealed that three factors were independent predictors of fair outcomes: (1) the Alberta Stroke Program Early CT Score (odds ratio [OR]: 1.79; 95% confidence interval [CI]: 1.16-2.78; <i>p</i> = 0.009); (2) Thrombolysis in Cerebral Infarction 2b to 3 (OR: 4.91; 95%CI: 1.10-21.89; <i>p</i> = 0.037); (3) the ratio of treatment-side blood flow between the internal carotid artery and common carotid artery (QTI/QTC, OR: 45.35; 95% CI: 1.11-1847.51; <i>p</i> = 0.04). <b>Conclusions</b>: The ratio of QTI/QTC is a clinically relevant parameter as a potential predictor of favorable outcomes. This parameter can be used to formulate patient prognostic scores and help clinicians determine whether adequate cerebral perfusion is maintained during the subacute phase.</p>","PeriodicalId":19130,"journal":{"name":"Neurology International","volume":"17 5","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12113688/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144151226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Variants in Neurotransmitter-Related Genes Are Associated with Alzheimer's Disease Risk and Cognitive Functioning but Not Short-Term Treatment Response.","authors":"Tirso Zúñiga-Santamaría, Blanca Estela Pérez-Aldana, Ingrid Fricke-Galindo, Margarita González-González, Zoila Gloria Trujillo-de Los Santos, Marie Catherine Boll-Woehrlen, Rosalía Rodríguez-García, Marisol López-López, Petra Yescas-Gómez","doi":"10.3390/neurolint17050065","DOIUrl":"10.3390/neurolint17050065","url":null,"abstract":"<p><p><b>Background/Objectives</b>: Several genetic factors are related to the risk of Alzheimer's disease (AD) and the response to cholinesterase inhibitors (ChEIs) (donepezil, galantamine, and rivastigmine) or memantine. However, findings have been controversial, and, to the best of our knowledge, admixed populations have not been previously evaluated. We aimed to determine the impact of genetic and non-genetic factors on the risk of AD and the short-term response to ChEIs and memantine in patients with AD from Mexico. <b>Methods</b>: This study included 117 patients from two specialty hospitals in Mexico City, Mexico. We evaluated cognitive performance via clinical evaluations and neuropsychological tests. Nineteen variants in <i>ABCB1</i>, <i>ACHE</i>, <i>APOE</i>, <i>BCHE</i>, <i>CHAT</i>, <i>CYP2D6</i>, <i>CYP3A5</i>, <i>CHRNA7</i>, <i>NR1I2</i>, and <i>POR</i> were assessed through TaqMan assays or PCR. <b>Results</b>: Minor alleles of the <i>ABCB1</i> rs1045642, <i>ACHE</i> rs17884589, and <i>CHAT</i> rs2177370 and rs3793790 variants were associated with the risk of AD; meanwhile, <i>CHRNA7</i> rs6494223 and <i>CYP3A5</i> rs776746 were identified as low-risk variants in AD. <i>BCHE</i> rs1803274 was associated with worse cognitive functioning. None of the genetic and non-genetic factors studied were associated with the response to pharmacological treatment. <b>Conclusions</b>: We identified potential genetic variants related to the risk of AD; meanwhile, no factor was observed to impact the response to pharmacological therapy in patients with AD from Mexico.</p>","PeriodicalId":19130,"journal":{"name":"Neurology International","volume":"17 5","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12114220/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144151238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epilepsy Diagnosis When the Routine Ancillary Tests Are Normal.","authors":"Boulenouar Mesraoua, Bassel Abou-Khalil, Bernhard Schuknecht, Hassan Al Hail, Musab Ali, Majd A AbuAlrob, Khaled Zammar, Ali A Asadi-Pooya","doi":"10.3390/neurolint17050066","DOIUrl":"10.3390/neurolint17050066","url":null,"abstract":"<p><p><b>Background/Objectives:</b> In a patient suspected of having epilepsy, routine EEG primarily contributes to the recording of interictal epileptiform discharges (IEDs). Similarly, magnetic resonance imaging (MRI) has become the gold standard imaging technique for identifying epileptogenic structural brain abnormalities. Various EEG and MRI tools to improve epilepsy diagnosis will be presented. <b>Methods:</b> When the initial EEG fails to record IEDs, various EEG measures that can improve EEG performance are presented; a comprehensive epilepsy-targeted MRI protocol to identify, localize, and characterize an epileptogenic lesion will also be described. <b>Results:</b> Studies show that the initial routine EEG fails to record IEDs in approximately 47-50% of epileptic patients. To improve the yield of EEG, subsequent EEG recording should include sleep deprivation, sleep recording, prolonged hyperventilation, optimized light stimulation, addition of an inferior temporal electrode chain, extended EEG duration, and continuous video-EEG monitoring, all measures known to activate IEDs. Furthermore, MRI is interpreted as \"normal\" in many epilepsy patients, even when performed according to an epilepsy-specific protocol and evaluated by a specialized MRI reader. In such case, the use of the Harmonized Epilepsy Structural Sequence Imaging (HARNESS-MRI) protocol and other imaging tools will improve the detection of potential epileptic lesions, as described in this study. <b>Conclusions:</b> In a patient with a clinical diagnosis of epilepsy but a normal EEG and brain MRI, several options can improve the performance of subsequent EEG and MRI examinations, the subjects of this review.</p>","PeriodicalId":19130,"journal":{"name":"Neurology International","volume":"17 5","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12113856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144151076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iatrogenic Cerebral Amyloid Angiopathy After Childhood Brain Surgery: Novel Findings of MRI and CT.","authors":"Fumine Tanaka, Maki Umino, Megumi Matsukawa, Seiya Kishi, Ryota Kogue, Norikazu Kawada, Ken Kagawa, Takaya Utsunomiya, Hiroyuki Kajikawa, Hidehiro Ishikawa, Yuichiro Ii, Akihiro Shindo, Hajime Sakuma, Masayuki Maeda","doi":"10.3390/neurolint17050064","DOIUrl":"10.3390/neurolint17050064","url":null,"abstract":"<p><p><b>Background/Objectives</b>: A subtype of cerebral amyloid angiopathy (CAA), iatrogenic CAA (iCAA), has been increasingly reported. iCAA occurs primarily in patients who underwent surgery during childhood and is caused by the prion-like propagation of amyloid beta. This subtype of CAA tends to develop at a younger age than age-related CAA, usually before the age of 55. After a latency period of 20-40 years following surgery, it manifests as lobar intracerebral hemorrhage (ICH), cognitive impairment, or transient focal neurological episodes. Between 2023 and 2024, we observed four cases of possible iCAA, all of which had a history of neurosurgery during childhood. <b>Case presentation</b>: MRI findings for all cases revealed multiple lobar microbleeds. Two cases also showed cortical superficial siderosis and lobar ICH. Notably, contrast-enhanced 3D FLAIR demonstrated sulcal enhancement in two cases, and CT demonstrated cortical calcification in the bilateral posterior lobes in one case. <b>Conclusions</b>: Sulcal enhancement on contrast-enhanced 3D FLAIR and cortical calcification in the bilateral posterior lobes on CT may suggest advanced CAA in the present cases.</p>","PeriodicalId":19130,"journal":{"name":"Neurology International","volume":"17 5","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12114373/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144151211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functional Mobility Assessment in People with Multiple Sclerosis.","authors":"Ivana Sretenović, Srećko Potić, Goran Nedović, Gordana Odović, Ljiljana Šimpraga","doi":"10.3390/neurolint17050063","DOIUrl":"10.3390/neurolint17050063","url":null,"abstract":"<p><strong>Background/objectives: </strong>Functional mobility includes gait and balance. People with multiple sclerosis often experience gait impairment and difficulties with walking, as well as an increased risk of falling. The aim of the research was to assess functional mobility and to examine the relationship between gait and balance in people with multiple sclerosis, as well as the impact of falls on these two variables.</p><p><strong>Methods: </strong>The study sample consisted of 92 people with multiple sclerosis, with an average age of 45.10 (SD = 9.57) years, and both sexes (82.6% were female). The Activities-specific Balance Confidence Scale was used to assess an individual's confidence in maintaining balance throughout daily activities, and the 12-item Multiple Sclerosis Walking Scale was employed to evaluate the impact of multiple sclerosis on walking ability. Descriptive statistics, measures of central tendency, Pearson's correlations, and partial correlations were applied to the data.</p><p><strong>Results: </strong>The results indicated moderate gait impairment and a high level of function in people with multiple sclerosis. There was a correlation between confidence in maintaining balance and walking ability.</p><p><strong>Conclusions: </strong>The results of this study can be used to develop appropriate treatments and support programs for individuals with multiple sclerosis.</p>","PeriodicalId":19130,"journal":{"name":"Neurology International","volume":"17 5","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12113744/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144151208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying Factors Associated with the Efficacy of Lasmiditan 50 mg as an Acute Treatment for Migraine Attacks Under Various Dosing Conditions in Real-World Clinical Practice.","authors":"Takafumi Tanei, Shun Yamamoto, Satoshi Maesawa, Yusuke Nishimura, Tomotaka Ishizaki, Yoshitaka Nagashima, Yoshiki Ito, Miki Hashida, Takahiro Suzuki, Hajime Hamasaki, Toshihiko Wakabayashi, Ryuta Saito","doi":"10.3390/neurolint17050062","DOIUrl":"10.3390/neurolint17050062","url":null,"abstract":"<p><p><b>Background/Objectives</b>: Lasmiditan is a newly developed drug for the acute treatment of migraine attacks, but factors associated with its efficacy remain unclear. This study aimed to confirm the efficacy of lasmiditan started at 50 mg under various dosing conditions and identify factors associated with its efficacy. <b>Methods</b>: There are four reasons for prescribing lasmiditan: as an add-on to triptan, if triptan is ineffective, if triptan produces side effects, and when triptan is contraindicated. Lasmiditan was administered at a dose of 50 mg. The efficacy of lasmiditan was defined as the disappearance of headache or a 50% or greater reduction in headache intensity within two hours after dosing. This study included 108 patients with migraines who took lasmiditan. <b>Results</b>: The results for efficacy and the side effects of lasmiditan were as follows: effective without side effects (22), effective with mild side effects (32), ineffective (14), and severe side effects (40). The efficacy rate of lasmiditan 50 mg was 50.0% (54/108). The following factors were found to be associated with lasmiditan's efficacy: sex, migraine classification, calcium channel blockers, and anti-calcitonin gene-related peptide monoclonal antibody (CGRP-mAb) treatment. The overall incidence of side effects was 66.7%, and the dropout rate was 37.0%. Somnolence was more prevalent in the effective group, and other side effects were more prevalent in patients who dropped out due to the side effects of lasmiditan. <b>Conclusions</b>: Lasmiditan is likely to be effective in males with severe migraine classification and receiving CGRP-mAb treatment. If mild somnolence is a side effect, the drug can be continued and may be effective.</p>","PeriodicalId":19130,"journal":{"name":"Neurology International","volume":"17 5","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12114562/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144151214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}